This invention enhances eradication of the influenza virus, decreases harmful inflammation associated with influenza virus infection, promotes recovery of respiratory function, and reduces the risk of developing secondary bacterial infections in the respiratory system. This technology allows for the specific targeting of cell-surface proteins using monoclonal antibodies, resulting in modulated intracellular signaling. Specifically, this invention describes inhibition of inflammatory intracellular signaling mediated by the Surfactant Protein A receptor in macrophages through the use of monoclonal antibodies that target the receptor.
Application & Market Utility
Every year, influenza viruses infect millions of people worldwide, leading to hundreds of thousands of deaths and hundreds of millions of dollars in healthcare costs. Vaccines against influenza viruses do not protect against all strains of the virus, and must be updated frequently to remain effective. Current drugs used to treat infected patients are only moderately effective and their use is contraindicated in certain patient populations. Therefore, there is a significant unmet medical need for better influenza treatment strategies.
Seeking research collaboration and licensing opportunities.